Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 245

1.

Regulation of substrate utilization by the mitochondrial pyruvate carrier.

Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN, Metallo CM.

Mol Cell. 2014 Nov 6;56(3):425-35. doi: 10.1016/j.molcel.2014.09.024. Epub 2014 Oct 30.

PMID:
25458843
[PubMed - in process]
2.

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.

Henry RR, Rosenstock J, Edelman S, Mudaliar S, Chalamandaris AG, Kasichayanula S, Bogle A, Iqbal N, List J, Griffen SC.

Diabetes Care. 2014 Sep 30. pii: DC_132955. [Epub ahead of print]

PMID:
25271207
[PubMed - as supplied by publisher]
3.

Status of Diabetes Care: "It just doesn't get any better . . . or does it?".

Cefalu WT, Boulton AJ, Tamborlane WV, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry RR, Hill Golden S, Rich S, Reynolds L.

Diabetes Care. 2014 Jul;37(7):1782-5. No abstract available.

PMID:
25093231
[PubMed - indexed for MEDLINE]
4.

Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.

Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H.

Diabetes Care. 2014 Sep;37(9):2609-15. doi: 10.2337/dc14-0210. Epub 2014 Jun 19.

PMID:
24947791
[PubMed - in process]
5.

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL; INT131-007 Study Group.

Diabetes Care. 2014 Jul;37(7):1918-23. doi: 10.2337/dc13-2480. Epub 2014 Apr 10.

PMID:
24722496
[PubMed - indexed for MEDLINE]
6.

Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.

Tripathy D, Clement SC, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, DeFronzo RA.

Diabetes Care. 2014 Jun;37(6):1706-11. doi: 10.2337/dc13-1745. Epub 2014 Apr 4.

PMID:
24705615
[PubMed - indexed for MEDLINE]
7.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators.

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
[PubMed - indexed for MEDLINE]
8.

Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program.

Dabelea D, Ma Y, Knowler WC, Marcovina S, Saudek CD, Arakaki R, White NH, Kahn SE, Orchard TJ, Goldberg R, Palmer J, Hamman RF; Diabetes Prevention Program Research Group.

Diabet Med. 2014 Sep;31(9):1064-8. doi: 10.1111/dme.12437. Epub 2014 Apr 9.

PMID:
24646311
[PubMed - in process]
9.

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.

Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA.

J Diabetes Complications. 2014 May-Jun;28(3):393-8. doi: 10.1016/j.jdiacomp.2013.12.009. Epub 2014 Jan 7.

PMID:
24631129
[PubMed - in process]
Free Article
10.

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.

Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J.

J Diabetes Complications. 2014 May-Jun;28(3):399-405. doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21.

PMID:
24561125
[PubMed - in process]
Free PMC Article
11.

Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program.

Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ; Diabetes Prevention Program Research Group.

Diabetologia. 2014 May;57(5):935-9. doi: 10.1007/s00125-014-3183-2. Epub 2014 Feb 20.

PMID:
24554005
[PubMed - indexed for MEDLINE]
12.

Short and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence.

Venditti EM, Wylie-Rosett J, Delahanty LM, Mele L, Hoskin MA, Edelstein SL; Diabetes Prevention Program Research Group.

Int J Behav Nutr Phys Act. 2014 Feb 12;11:16. doi: 10.1186/1479-5868-11-16.

PMID:
24521153
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.

Franks PW, Christophi CA, Jablonski KA, Billings LK, Delahanty LM, Horton ES, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetologia. 2014 Mar;57(3):485-90. doi: 10.1007/s00125-013-3133-4. Epub 2013 Dec 7.

PMID:
24317794
[PubMed - in process]
14.

Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation.

Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, Barboza J, Taub PR, Hogan MC, Henry RR, Meaney E, Villarreal F, Ceballos G, Ramirez-Sanchez I.

J Nutr Biochem. 2014 Jan;25(1):91-4. doi: 10.1016/j.jnutbio.2013.09.007. Epub 2013 Oct 18.

PMID:
24314870
[PubMed - indexed for MEDLINE]
15.

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.

Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Duchesne D, Iqbal N, List J.

Diabetes Technol Ther. 2014 Mar;16(3):137-44. doi: 10.1089/dia.2013.0167. Epub 2013 Nov 15.

PMID:
24237386
[PubMed - indexed for MEDLINE]
16.

Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk.

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study.

Diabetes Care. 2013 Nov;36(11):3607-12. doi: 10.2337/dc13-0520. Epub 2013 Sep 23.

PMID:
24062330
[PubMed - in process]
Free PMC Article
17.

Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity.

Meyer LK, Ciaraldi TP, Henry RR, Wittgrove AC, Phillips SA.

Adipocyte. 2013 Oct 1;2(4):217-26. doi: 10.4161/adip.24953. Epub 2013 May 7.

PMID:
24052897
[PubMed]
Free PMC Article
18.

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE.

Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013. Epub 2013 Jul 26.

PMID:
24016490
[PubMed - indexed for MEDLINE]
19.

Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.

Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR.

Metabolism. 2013 Nov;62(11):1587-96. doi: 10.1016/j.metabol.2013.07.004. Epub 2013 Aug 17.

PMID:
23958241
[PubMed - indexed for MEDLINE]
20.

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study.

Henry RR, Staels B, Fonseca VA, Chou MZ, Teng R, Golm GT, Langdon RB, Kaufman KD, Steinberg H, Goldstein BJ.

Diabetes Obes Metab. 2014 Mar;16(3):223-30. doi: 10.1111/dom.12194. Epub 2013 Aug 29.

PMID:
23909985
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk